“EP” PRESSURE CELL HOMOGENISER

Importance of the topic

High-pressure pressure-cell homogenisation and cell disruption remain foundational techniques in life sciences, pharmaceutical development, cosmetics and advanced materials. They enable efficient mechanical rupture of cells, generation of submicron emulsions and particle size reduction required for reproducible nanoparticle, liposome and suspension production. Reliable, safe and scalable high-pressure systems are essential for bridging laboratory research and pilot or production-scale manufacturing while maintaining sterility, temperature control and process reproducibility.

Objectives and overview of the product

This product summary describes the updated Stansted range of pressure-cell homogenisers from Homogenising Systems. The objective is to present a modernised instrument family combining the established advantages of pressure-cell disruption (simplicity, robust processing of biological samples) with higher performance, enhanced safety interlocks, microprocessor control and expanded process flexibility. The range targets multidisciplinary applications from basic cell-rupture research to pilot-scale production of nanoemulsions and dispersions.

Used instrumentation

• Model family: Pressure-cell homogenisers S-PCH series (Stansted range).
• Cell options and nominal performance:
  • S-PCH-10: 4200 bar (60,000 psi), 10 ml cell, flow up to 60 ml·min⁻¹, nominal motor 1.1 kW.
  • S-PCH-20: 2100 bar (30,000 psi), 18 ml cell, flow up to 115 ml·min⁻¹, 1.1 kW.
  • S-PCH-35: 1050 bar (15,000 psi), 35 ml cell, flow up to 230 ml·min⁻¹, 1.1 kW.
  • S-PCH-01: 2700 bar (40,000 psi), 1 ml ultra-low-volume cell, flow ~1 ml·min⁻¹, 1.1 kW.
• Disruption/homogenising valve options: high-shear piston-gap (HPVS-1) and reverse-flow piston-gap systems; interchangeable and refurbishable valve/cell configurations.
• Process control: microprocessor-controlled unit offering full pressure adjustment, variable flow (including drop-by-drop), single-shot and continuous cycling modes, and safety interlocks compliant with CE and international standards.
• Temperature and downstream options: air-cooled outlet cooler (AC-HX) for small volumes; liquid-cooled outlet cooler (LC-HX) and cell-body heat exchanger (CB-HX) for larger volumes (require external fluid circulation); pressurised transparent product feed chambers (PFS) 0.25–5 L; optional back-pressure (second-stage) valve for two-stage processing.
• Physical and utility details: basic dimensions ~550 mm (W) × 600 mm (D) × 670 mm (H); weight ~110 kg; electrical supply options 230 V 1ph 50 Hz or 110 V 1ph 60 Hz (other voltages available on request).

Methodology and operating principles

The instrument operates by forcing sample material through a high-pressure cell and a disruption valve to produce intense shear, impact and cavitation forces that break cells and reduce particle sizes. Key operational features include:

• Wide pressure flexibility up to 4200 bar (60,000 psi) depending on cell selection to tailor shear intensity to sample type.
• Interchangeable cells and valve geometries to optimise for cell rupture, emulsification, or nanoparticle dispersion.
• Microprocessor control enabling reproducible pressure setpoints, automated cycling (single-shot or continuous), and fine flow-rate control, including very low-volume processing for precious samples.
• Temperature management through integrated or optional heat exchangers to limit thermally induced sample damage during high-energy processing.
• Reverse-flow piston-gap option to mitigate fouling and allow inspectable/refurbishable valve geometries, improving uptime and maintenance.

Main results and discussion

The documented product capabilities indicate a platform suitable for multiple laboratory-to-pilot applications. Practical capabilities and implications include:

• Biological disruption: effective mechanical lysis of bacteria (e.g., E. coli), yeast, staphylococci and mammalian cells with small sample volumes and sterile-capable cell/valve designs.
• Nanoscale formulation: generation of nanoemulsions, solid lipid nanoparticles, liposomes, microemulsions and dispersions; pressure and shear control enable tuning of particle size distributions.
• Throughput range: models cover low-volume, high-pressure needs (1–10 ml cells) up to larger-volume processing (18–35 ml cells) with flows from ~1 to 230 ml·min⁻¹, facilitating scale-up strategies within the same technology family.
• Reproducibility and safety: microprocessor control, safety interlocks and sterile components support reproducible processing under safe, compliant conditions suitable for research and regulated environments.
• Operational flexibility: features such as two-stage pressure control, variable flow (including dropwise), cooled outlets and pressurised feed chambers broaden the range of process conditions and sample types that can be handled.

Benefits and practical applications

The system offers several practical advantages for laboratories and production facilities:

• Versatility across disciplines: biotech, pharmaceutical formulation, cosmetics, chemical processing and nanomaterials research.
• Small-sample handling: ultra-low-volume cells allow processing precious or scarce material while maintaining representative processing conditions for scale-up.
• Sterilisable components and temperature control support aseptic workflows and thermally sensitive formulations.
• Scalability: matched technology up- and downstream (pilot and production models available) eases technology transfer from R&D to manufacturing.
• Serviceability: inspectable, refurbishable valve and cell designs reduce lifecycle costs and downtime.

Future trends and applications

Anticipated developments and application trends for high-pressure homogenisation technology include:

• Greater integration with process analytical technology (PAT) and in-line particle size/viscosity measurement for closed-loop control of product quality.
• Improved automation and recipe management for higher throughput regulated environments and GMP-compatible workflows.
• Hybrid approaches combining high-pressure homogenisation with microfluidics or ultrasonic pre/post-treatment to broaden formulation windows and reduce energy input.
• Enhanced thermal management and aseptic modules to support biologics and vaccine manufacturing under stringent temperature and sterility constraints.
• Material- and surface-engineered valve/cell components to reduce fouling, extend run lengths and enable more aggressive chemistries.

Conclusion

The updated Stansted pressure-cell homogeniser family provides a modernised, flexible platform for both cell disruption and high-energy formulation tasks. With pressures reaching up to 4200 bar, microprocessor control, sterilizable components and a spectrum of cell sizes and valve geometries, the range supports reproducible laboratory studies and provides clear pathways to pilot or production scale. Optional cooling, two-stage capabilities and serviceable valve designs further increase the practical utility for multidisciplinary users seeking robust, scalable mechanical processing solutions.

Reference

Homogenising Systems Limited, Stansted range pressure cell homogeniser product brochure, V5.0, 11-02-2018. Contact and product information supplied by Homogenising Systems Ltd., Harlow, Essex, UK.